Table 1 Baseline clinicopathologic characteristics of patients
Total N = 52 (%) | TMB high (> 9.68 mut/Mb) N = 26 (%) | TMB low (≤ 9.68 mut/Mb) N = 26 (%) | P-valuea | ||
|---|---|---|---|---|---|
Age | Median | 65 | 63.5 | 67.5 | 0.18 |
Range | 43–84 | 47–84 | 43–83 | ||
Sex | Male | 25 (48.1) | 10 (38.5) | 15 (57.7) | 0.27 |
Female | 27 (51.9) | 16 (61.5) | 11 (42.3) | ||
Smoking Status | Current/Former | 49 (94.2) | 26 (100) | 23 (88.5) | 0.24 |
Never | 3 (5.8) | 0 (0.0) | 3 (11.5) | ||
EGFR status | Mutant | 3 (5.8) | 0 (0.0) | 3 (11.5) | 0.24 |
Wild type | 49 (94.2) | 26 (100) | 23 (88.5) | ||
Stage at Diagnosis | Extensive | 34 (65.4) | 15 (57.7) | 19 (73.1) | 0.38 |
Limited | 18 (34.6) | 11 (42.3) | 7 (26.9) | ||
ECOG PS | 0 | 7 (13.5) | 3 (11.5) | 4 (15.4) | 0.24b |
1 | 28 (53.8) | 17 (65.4) | 11 (42.3) | ||
2 | 15 (28.8) | 5 (19.2) | 10 (38.5) | ||
3 | 2 (3.8) | 1 (3.8) | 1 (3.8) | ||
Response to platinum doublet | Platinum sensitive | 26 (50.0) | 15 (57.7) | 11 (42.3) | 0.41c |
Platinum resistant | 19 (36.5) | 10 (38.5) | 9 (34.6) | ||
Platinum refractory | 7 (13.5) | 1 (3.8) | 6 (23.1) | ||
Treatment received | PD-1-monotherapyd | 31 (59.6) | 17 (65.4) | 14 (53.8) | 0.57 |
PD-1 + CTLA-4 | 21 (40.4) | 9 (34.6) | 12 (46.2) | ||
Treatment setting | Clinical trial | 22 (42.3) | 14 (53.8) | 8 (30.8) | 0.16 |
Commercial | 30 (57.7) | 12 (46.2) | 18 (69.2) | ||
Line of therapy | 2 | 29 (55.8) | 18 (69.2) | 11 (42.3) | 0.09e |
3 | 15 (28.8) | 6 (23.1) | 9 (34.6) | ||
≥ 4 | 8 (15.4) | 2 (7.7) | 6 (23.1) | ||
Brain metastasis prior to immunotherapy | Yes | 17 (32.7) | 7 (26.9) | 10 (38.5) | 0.56 |
No | 35 (67.3) | 19 (73.1) | 16 (61.5) |